Claims
- 1. A method for inducing immunity against Chlamydia in a mammalian subject, the method comprising:
administering to a mammalian subject a PorB vaccine in an amount sufficient to elicit an immune response; wherein said immune response is sufficient to decrease risk of onset of disease caused by Chlamydia.
- 2. The method of claim 1, wherein the vaccine comprises a PorB polypeptide of Chlamydia trachomatis.
- 3. The method of claim 1, wherein the vaccine comprises a PorB polypeptide of Chlamydia pneumoniae.
- 4. The method of claim 1, wherein the vaccine comprises a PorB polypeptide of Chlamydia psittaci.
- 5. The method of claim 1, wherein the vaccine comprises nucleic acid encoding a PorB polypeptide for expression in the subject.
- 6. The method of claim 1, wherein the vaccine comprises a recombinant live vaccine which comprises a PorB polypeptide-encoding polynucleotide.
- 7. The method of claim 6, wherein the live vaccine is a recombinant virus comprising a PorB polypeptide-encoding polynucleotide for expression in the subject.
- 8. The method of claim 1, wherein the vaccine comprises a PorB polypeptide and said administering is subcutaneous, intramuscular, intradermal, or intravenous.
- 9. The method of claim 1, wherein the vaccine comprises a nucleic acid encoding a PorB polypeptide and wherein said administering subcutaneous, transdermal, subdermal, intradermal, topical, or intramuscular.
- 10. A vaccine composition comprising:
an isolated PorB polypeptide in an amount effective to induce an immune response in a subject; and a pharmaceutically acceptable carrier.
- 11. The vaccine composition of claim 10, wherein the PorB polypeptide is a PorB polypeptide of C. trachomatis.
- 12. The vaccine composition of claim 10, wherein the PorB polypeptide is a PorB polypeptide of C. pneumoniae.
- 13. The vaccine composition of claim 10, wherein the PorB polypeptide is a PorB polypeptide of C. psittaci.
- 14. A vaccine composition comprising:
an isolated polynucleotide comprising a sequence encoding a PorB polypeptide, the polynucleotide being present in an amount effective to provide for production of the PorB polypeptide in a host in an amount sufficient to induce an immune response in a subject; and a pharmaceutically acceptable carrier.
- 15. The vaccine composition of claim 14, wherein the PorB polypeptide is a PorB polypeptide of C. trachomatis.
- 16. The vaccine composition of claim 14, wherein the PorB polypeptide is a PorB polypeptide of C. pneumoniae.
- 17. The vaccine composition of claim 14, wherein the PorB polypeptide is a PorB polypeptide of C. psittaci.
- 18. A method of providing a subject with protective immunity to chlamydial infection, the method comprising:
administering to a subject an amount of an antibody that specifically binds a PorB polypeptide, the amount being effective to inhibit or mitigate chlamydial infection in the subject.
- 19. A method for determining exposure of a subject to a Chlamydia infection, the method comprising:
contacting a biological sample from a subject suspected having been exposed to Chlamydia or having a Chlamydia infection with a) an antibody that specifically binds a PorB polypeptide or b) a PorB polypeptide, said contacting being under conditions sufficient to allow for formation of specific antibody-PorB polypeptide binding pairs; and detecting the antibody-PorB binding pairs; wherein detection of the antibody-PorB binding pairs indicates the subject has been exposed to infection by Chlamydia.
- 20. A method for detecting a Chlamydia infection in a subject, the method comprising:
contacting a test sample from a subject suspected of having a chlamydial infection with a probe, the probe being selected from the group consisting of a) a PorB polypeptide that can be bound by a PorB-specific antibody, b) a specific PorB antibody; and c) a PorB polypeptide-encoding polynucleotide; and detecting binding of the probe to the test sample; wherein detection of binding of the probe to the test sample is indicative of Chlamydia infection in the subject.
- 21. The method of claim 20, wherein the probe is an anti-PorB antibody for detection of a PorB polypeptide in the test sample.
- 22. The method of claim 20, wherein the probe is a PorB polypeptide for detection of an anti-PorB antibody in the test sample.
- 23. The method of claim 20, wherein the probe is a PorB polynucleotide for detection of a PorB polypeptide-encoding polynucleotide in the test sample.
- 24. A method for identifying an agent that inhibits PorB function, the method comprising:
contacting a PorB polypeptide with a candidate agent; and determining the effect of the candidate agent on PorB activity in transport of α-ketoglutarate.
- 25. The method of claim 24, wherein the PorB polypeptide is present in a membrane.
- 26. The method of claim 24, wherein the membrane is an artificial membrane.
- 27. The method of claim 26, wherein the artificial membrane is a membrane of a liposome.
- 28. The method of claim 25, wherein the membrane is an extracellular membrane of a host cell.
- 29. A method for identifying an agent that inhibits PorB function, the method comprising:
combining a liposome comprising a PorB polypeptide with a candidate agent and α-ketoglutarate; and determining the effect of the candidate agent on PorB activity in transport of α-ketoglutarate; wherein a decrease in transport of α-ketoglutarate indicates that the agent inhibits PorB function.
STATEMENT As To FEDERALLY SPONSORED RESEARCH
[0001] This invention was made, at least in part, with a government grant from the National Institutes of Health (Grant Nos. NIH grants AI40250, AI39258, and AI42156). Thus, the U.S. government may have certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60179592 |
Feb 2000 |
US |